Compare GENC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | IMUX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 188.8M |
| IPO Year | 1995 | 2013 |
| Metric | GENC | IMUX |
|---|---|---|
| Price | $15.01 | $14.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $17.60 | ★ $36.00 |
| AVG Volume (30 Days) | 29.6K | ★ 229.8K |
| Earning Date | 02-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 38.00 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.51 | N/A |
| P/E Ratio | $29.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.22 | $0.51 |
| 52 Week High | $17.40 | $15.77 |
| Indicator | GENC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 50.00 | 62.08 |
| Support Level | $14.57 | $0.74 |
| Resistance Level | $15.62 | $15.77 |
| Average True Range (ATR) | 0.47 | 1.20 |
| MACD | 0.03 | -0.25 |
| Stochastic Oscillator | 47.33 | 60.66 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.